Project Duration: August 31, 2012 to August 30, 2013
This program is part of a national initiative (QUEST) to compare the durability and efficacy of 2 different vaccination programs against HPV in girls ages 9-12. Participants are enrolled across Canada. Vaccine is given as either 2-doses or 3-doses as part of a larger clinical trial. Participants are followed until age 19 or 120 months after the first dose of vaccine. Endpoints include assessment of type specific persistent HPV infection from self-collected vaginal specimens and serum, and monitoring the antibody in the two different vaccination groups
